Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16025229rdf:typepubmed:Citationlld:pubmed
pubmed-article:16025229lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:16025229lifeskim:mentionsumls-concept:C0018270lld:lifeskim
pubmed-article:16025229lifeskim:mentionsumls-concept:C0178587lld:lifeskim
pubmed-article:16025229lifeskim:mentionsumls-concept:C0237477lld:lifeskim
pubmed-article:16025229pubmed:issue2lld:pubmed
pubmed-article:16025229pubmed:dateCreated2005-7-18lld:pubmed
pubmed-article:16025229pubmed:abstractTextAn important issue in atherosclerosis is the timing of intimal microvascular formation and its relation to the initiation of plaque formation. Monocytes and endothelial cells (ECs) are important cell components in these steps. Statins not only reduce atherogenic low density lipoprotein cholesterol, they also increase high density lipoprotein-cholesterol (HDL). Although a higher concentration of statin has an anti-proliferative effect, HDL is potentially mitogenic. Therefore, we examined the opposing effects of statin, Apo-AI, HDL and HDL fractions on cell proliferation and apoptosis in monocytes and on angiogenesis in ECs. A high concentration of simvastatin inhibited monocyte proliferation as evaluated by counting cell numbers using a hematocytometer. This inhibition was mainly blocked by the HDL3 subfraction. The same concentration of simvastatin induced apoptosis as assessed by the fluorescence-labeled annexin-V method through caspase-3 activation in monocytes. HDL inhibited simvastatin-induced apoptosis. In addition, HDL blocked simvastatin-inhibited angiogenesis in an in vitro model of EC tube formation. In conclusion, the compensatory balance between the effects of statin and HDL may play an important role in the formation of atherosclerotic lesions by affecting proliferation and apoptosis in monocytes and angiogenesis in ECs.lld:pubmed
pubmed-article:16025229pubmed:languageenglld:pubmed
pubmed-article:16025229pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:citationSubsetIMlld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16025229pubmed:statusMEDLINElld:pubmed
pubmed-article:16025229pubmed:monthMarlld:pubmed
pubmed-article:16025229pubmed:issn0920-3206lld:pubmed
pubmed-article:16025229pubmed:authorpubmed-author:SakuKeijiroKlld:pubmed
pubmed-article:16025229pubmed:authorpubmed-author:MiuraShin-Ich...lld:pubmed
pubmed-article:16025229pubmed:authorpubmed-author:FujinoMasahir...lld:pubmed
pubmed-article:16025229pubmed:authorpubmed-author:TanigawaHiroy...lld:pubmed
pubmed-article:16025229pubmed:authorpubmed-author:MatsuoYoshino...lld:pubmed
pubmed-article:16025229pubmed:issnTypePrintlld:pubmed
pubmed-article:16025229pubmed:volume19lld:pubmed
pubmed-article:16025229pubmed:ownerNLMlld:pubmed
pubmed-article:16025229pubmed:authorsCompleteYlld:pubmed
pubmed-article:16025229pubmed:pagination113-8lld:pubmed
pubmed-article:16025229pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:meshHeadingpubmed-meshheading:16025229...lld:pubmed
pubmed-article:16025229pubmed:year2005lld:pubmed
pubmed-article:16025229pubmed:articleTitleCounteracting effects of high density lipoprotein-cholesterol subfractions on statin-induced growth arrest.lld:pubmed
pubmed-article:16025229pubmed:affiliationDepartment of Cardiology, Fukuoka University School of Medicine, Fukuoka, Japan.lld:pubmed
pubmed-article:16025229pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16025229pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:16025229pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed